RavenQuest Announces Key Changes to Its Board of Directors
01 November 2019 - 9:00PM
RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt:
1IT) (the “
Company” or
“
RavenQuest”), one of Canada’s most innovative
cannabis companies, announces that Mark Percival and Mark
Ahrens-Townsend have been elected as directors of the Company at
its annual general meeting held on October 30, 2019. Further
information on each can be found below. Messrs. Percival and
Ahrens-Townsend fill the vacancies created by Chris Bechtel and Dr.
Jorge Bonet, who did not stand for re-election at the meeting.
“As RavenQuest continues to lead the industry as
an innovator among cannabis companies, it is important that the
composition, experience and expertise of our board continues to
align with the Company's strategic direction,” said George
Robinson, CEO of RavenQuest. “I’m confident that the changes
announced today will ensure our board will continue to provide
robust oversight and leadership as we embark upon the production
era of our growing company,” Robinson continued.
“RavenQuest wishes to thank Mr. Bechtel and Dr.
Bonet for their contribution to the Company. During our early
days as a public entity, both gentlemen were key contributors in
guiding our company through the many accomplishments it has made to
this point,” stated Robinson.
Mark Percival
Dr. Mark Percival is the CEO of Nanosphere
Health Sciences Inc. and the owner of Health Coach Systems
International Inc. He has been a progressive health
professional and clinician for 33 years. He has also been a
corporate executive and co-founder of seven companies in the
healthcare industry over the last 24 years. His experience
compelled him to create the first health coach company, Health
Coach Systems International Inc. Founded in the late 80's, Health
Coach continuously challenged status quo in healthcare. Mark's
leadership and progressive approach led to international
recognition and roles in companies willing to challenge the status
quo and advance healthcare in important areas. In his role as CEO
of Health Coach Systems International Inc. Mark continued his work
through consulting on advancements in healthcare, augmenting human
performance and mitigating and preventing preventable illness. This
led to his study of medical cannabis and related technology. He
subsequently became an investor in the Corporation and the CEO of
Nanosphere Health Sciences Inc, an emerging publicly-traded
nano-biotechnology company.
Mark Ahrens-Townsend
Mr. Mark Ahrens-Townsend has spent over 35 years in the
technology, engineering and venture capital industries. For the
past 25 years he has held senior executive roles and has served as
President and CEO of three Canadian-based publicly traded companies
specializing in information, communication and bio technology. His
business experience spans North America, Europe and Asia. In
addition, he has also served extensively on the boards and
committees of several private and publicly held companies. Mr.
Ahrens-Townsend holds a B.Sc. (Engineering) and an MBA (Finance)
from the University of Manitoba.
For more information, access RavenQuest’s
investor presentation, fact sheet and videos here.
Follow
RavenQuest:TwitterInstagramFacebookLinkedIn
About RavenQuest BioMed Inc.
RavenQuest is a diversified publicly traded
cannabis company with divisions focused upon cannabis production,
management services & consulting and specialized research &
development. RavenQuest is a licensed producer with facilities
located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with
McGill University focused upon cultivar (strain) recognition, plant
stabilization and yield maximization of the cannabis plant.
The Company also focuses on partnerships with Indigenous
communities.
On Behalf of the Board of Directors
ofRAVENQUEST BIOMED INC.
“George Robinson”Chief Executive Officer
For further information, please contact: |
Mathieu McDonald, Corporate Communications |
|
1-877-282-1586 |
Neither the Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statement
All statements in this press release, other than
statements of historical fact, are “forward-looking information”
with respect to the Company within the meaning of applicable
securities laws. The Company provides forward-looking statements
for the purpose of conveying information about current expectations
and plans relating to the future and readers are cautioned that
such statements may not be appropriate for other purposes. By its
nature, this information is subject to inherent risks and
uncertainties that may be general or specific and which give rise
to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. These risks and uncertainties
include but are not limited those identified and reported in the
Company’s public filings under the Company’s SEDAR profile at
www.sedar.com. Although the Company has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements. The
Company disclaims any intention or obligation to update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
RavenQuest BioMed (CSE:RQB)
Historical Stock Chart
From Nov 2024 to Dec 2024
RavenQuest BioMed (CSE:RQB)
Historical Stock Chart
From Dec 2023 to Dec 2024